Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 10.88% is 457% above its 5-year average of -3.04%, around the middle of its 5-year range (-97.43%–61.14%).
15.51% above its 12-month average of 9.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 13.31%.
EBITDA MARGIN
10.88%
EBITDA MARGIN AVG TTM
9.42%
EBITDA MARGIN AVG 3Y
10.21%
EBITDA MARGIN AVG 5Y
-3.04%
EBITDA MARGIN AVG 10Y
-48.55%
EBITDA MARGIN AVG 15Y
-310.48%
EBITDA MARGIN AVG 20Y
-385.99%
CURRENT VS TTM AVG
+15.51%
CURRENT VS 3Y AVG
+6.55%
CURRENT VS 5Y AVG
+457.41%
CURRENT VS 10Y AVG
+122.41%
CURRENT VS 15Y AVG
+103.50%
CURRENT VS 20Y AVG
+102.82%
Acadia Pharmaceuticals Inc.
Market Cap
$3.44B
EBITDA Margin
10.88%
TTM Avg
9.42%
3Y Avg
10.21%
5Y Avg
-3.04%
Market Cap
$3.16B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$3.15B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
Market Cap
$3.09B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$2.88B
EBITDA Margin
89.92%
TTM Avg
49.57%
3Y Avg
44.47%
5Y Avg
4968.54%
Market Cap
$2.87B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.44B | 10.88% | 9.42% | 10.21% | -3.04% |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.61B | -1.23% | 8.45% | -16.90% | -13.40% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -54.45% | -179.51% | -231.98% | -287.87% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -359.19% | -174.35% | -417.41% | -1450.57% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 89.92% | 49.57% | 44.47% | 4968.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 22.42% | 17.70% | -0.76% | -37.34% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 3.20% | -0.69% | -3.43% | -1.09% |
Gross Margin
91.1%
EBITDA Margin
10.9%
Operating Margin
7.6%
Net Margin
33.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 13.31% |
| 2026-03-31 | -0.61% |
| 2025-12-31 | 7.15% |
| 2025-09-30 | 13.89% |
| 2025-06-30 | 13.35% |
| 2025-03-31 | 9.10% |
| 2024-12-31 | 61.14% |
| 2024-09-30 | 13.66% |
| 2024-06-30 | 13.64% |
| 2024-03-31 | 10.08% |
| 2023-12-31 | 15.83% |
| 2023-09-30 | -26.48% |
| 2023-06-30 | 2.91% |
| 2023-03-31 | -44.87% |
| 2022-12-31 | -33.39% |
| 2022-09-30 | -23.23% |
| 2022-06-30 | -24.62% |
| 2022-03-31 | -97.43% |
| 2021-12-31 | -33.74% |
| 2021-09-30 | -10.88% |
| 2021-06-30 | -37.13% |
| 2021-03-31 | -61.82% |
| 2020-12-31 | -54.81% |
| 2020-09-30 | -70.65% |
| 2020-06-30 | -39.32% |
| 2020-03-31 | -98.65% |
| 2019-12-31 | -56.71% |
| 2019-09-30 | -47.33% |
| 2019-06-30 | -67.78% |
| 2019-03-31 | -137.95% |
| 2018-12-31 | -111.62% |
| 2018-09-30 | -103.80% |
| 2018-06-30 | -111.05% |
| 2018-03-31 | -110.62% |
| 2017-12-31 | -159.10% |
| 2017-09-30 | -184.42% |
| 2017-06-30 | -222.34% |
| 2017-03-31 | -576.78% |
| 2016-12-31 | -648.73% |
| 2016-09-30 | -1362.74% |
| 2016-06-30 | -73683.51% |
| 2016-03-31 | -1253100.00% |
| 2015-12-31 | -267276.47% |
| 2015-09-30 | -99694.87% |
| 2015-06-30 | -3921700.00% |
| 2015-03-31 | -1010750.00% |
| 2014-12-31 | -60625.53% |
| 2014-09-30 | -166226.67% |
| 2014-06-30 | -77432.14% |
| 2014-03-31 | -59716.67% |
| 2013-12-31 | -32770.27% |
| 2013-09-30 | -4497.92% |
| 2013-06-30 | -2027.72% |
| 2013-03-31 | -1475.30% |
| 2012-12-31 | -1788.95% |
| 2012-09-30 | -68.37% |
| 2012-06-30 | -901.50% |
| 2012-03-31 | -1378.00% |
| 2011-12-31 | -898.64% |
| 2011-09-30 | -866.95% |
| 2011-06-30 | -1423.48% |
| 2011-03-31 | -1303.91% |
| 2010-12-31 | 82.82% |
| 2010-09-30 | -179.97% |
| 2010-06-30 | -181.02% |
| 2010-03-31 | -249.51% |
| 2009-12-31 | -467.04% |
| 2009-09-30 | -351.33% |
| 2009-06-30 | -692.20% |
| 2009-03-31 | -3995.45% |
| 2008-09-30 | -5428.72% |
| 2008-06-30 | -10467.80% |
| 2008-03-31 | -2267.74% |
| 2007-12-31 | -1134.62% |
| 2007-03-31 | -665.71% |
| 2006-09-30 | -634.07% |
| 2006-06-30 | -673.52% |
| 2006-03-31 | -390.66% |
| 2005-12-31 | -429.54% |
| 2005-09-30 | -342.77% |
| 2005-06-30 | -246.60% |
| 2005-03-31 | -236.29% |
| 2004-12-31 | -655.17% |
| 2004-09-30 | -380.52% |
| 2004-06-30 | -549.07% |
| 2004-03-31 | -659.96% |
| 2003-12-31 | -1044.88% |
| 2003-09-30 | 100.00% |
| 2003-06-30 | -89.52% |
| 2003-03-31 | -123.33% |
